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In acute heart failure (AHF) syndromes significant respiratory failure (RF) is essentially seen in patients with acute cardiogenic pulmonary
oedema (ACPE) or cardiogenic shock (CS). Non-invasive ventilation (NIV), the application of positive intrathoracic pressure through an
interface, has shown to be useful in the treatment of moderate to severe RF in several scenarios. There are two main modalities of NIV:
continuous positive airway pressure (CPAP) and pressure support ventilation (NIPSV) with positive end expiratory pressure. Appropriate
equipment and experience is needed for NIPSV, whereas CPAP may be administered without a ventilator, not requiring special training.
Both modalities have shown to be effective in ACPE, by a reduction of respiratory distress and the endotracheal intubation rate compared
to conventional oxygen therapy, but the impact on mortality is less conclusive. Non-invasive ventilation is also indicated in patients with
AHF associated to pulmonary disease and may be considered, after haemodynamic stabilization, in some patients with CS. There are no
differences in the outcomes in the studies comparing both techniques, but CPAP is a simpler technique that may be preferred in low-
equipped areas like the pre-hospital setting, while NIPSV may be preferable in patients with significant hypercapnia. The new modality
‘high-flow nasal cannula’ seems promising in cases of AHF with less severe RF. The correct selection of patients and interfaces, early
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application of the technique, the achievement of a good synchrony between patients and the ventilator avoiding excessive leakage, close
monitoring, proactive management, and in some cases mild sedation, may warrant the success of the technique.
...................................................................................................................................................................................................
Keywords Non-invasive ventilation • CPAP • Bilevel pressure support • Acute heart failure • Acute cardiogenic pul-
monary oedema • High-flow nasal cannula
Introduction
Acute respiratory failure (RF), defined as fall in blood oxygen concen-
tration (hypoxaemia) with or without hypercapnia, is one of the most
important causes of emergency department presentation in adults.
High-flow ‘Venturi’ masks and low-flow reservoir masks or thin nasal
cannulas are the standard forms of conventional oxygen therapy
(COT) to treat these patients. However, RF is not often fully compen-
sated with COT and requires greater respiratory support.
Traditionally, this was only provided by a ventilator, generating posi-
tive intrathoracic pressure (PIP) via endotracheal intubation (EI).
Nevertheless, EI carries its own risks, and usually requires complete
sedation and admission to a critical care area. Non-invasive ventilation
(NIV) is a technique that emerged in the 1980’s, that consists of apply-
ing positive pressure to conscious patients through different interfa-
ces, it has been shown to be useful in acute RF, reducing the need for
EI and decreasing its associated risk of infection, mainly ventilator-
associated pneumonia.1 Since its introduction, NIV has been extended
to different areas of the hospital, the pre-hospital setting and even
domiciliary care, while ventilation through EI has remained limited to
critical units or the operating theatre. Non-invasive ventilation is indi-
cated to treat RF in a range of different scenarios, including dysfunc-
tion of the nervous system, muscles, chest wall, airways, and lung
parenchyma, such as acute heart failure (AHF).
Acute respiratory failure in acute
heart failure syndromes
Pulmonary oedema is the second most frequent (after pneumonia)
acute parenchymal alteration causing RF. Some degree of pulmonary
(interstitial/alveolar) oedema may be observed in most of patients
with AHF syndromes.2 Consequently, nearly 90% of AHF patients
complain of dyspnoea,3 but fewer than half present with RF affecting
the blood gas analysis, in form of hypoxaemia, hypercapnia, acidosis,
or a combination thereof.4 In relation to the different AHF syn-
dromes, significant RF is primarily seen in acute cardiogenic pulmo-
nary oedema (ACPE), in cardiogenic shock (CS) and in cases
associated to other lung alterations.2,5
Acute cardiogenic pulmonary oedema: The hallmark of this syndrome
is a rapid increase in pulmonary capillary hydrostatic pressure and
trans-vascular fluid filtration that exceeds the lymphatic interstitial
drainage capacity.6 Respiratory failure occurs when an excess of
interstitial and alveoli fluid results in a significant reduction of gas
exchange and a concomitant shunt effect. Acute cardiogenic pulmo-
nary oedema is a stressful scenario with progressive RF that may lead
to cardiorespiratory collapse in hours, or minutes, unless therapeutic
action is taken. Several clinical criteria are required for the diagnosis
of ACPE (Table 1).7,8 Initial bedside assessment using the clinical crite-
ria allows the initiation of urgent therapies, but the diagnosis should
be confirmed thereafter by additional criteria, more specific for AHF.
Key clinical findings are respiratory distress and RF. Other AHF sce-
narios with interstitial or mild alveolar oedema without significant RF
or respiratory distress would not be considered ACPE.
The rate and speed of alveolar fluid filtration, microvascular mem-
brane permeability, alteration in sodium-chloride and water reab-
sorption, as well as inflammation and individual genetic susceptibility
.................................................................................................
Table 1 Diagnostic criteria for acute cardiogenic pul-
monary oedema
Clinical criteria (all of them)
• Acute respiratory distress1
• Physical examination2
• Orthopnoea
• Respiratory failure3
Diagnostic confirmation (at least two of the following)
• Clear signs of pulmonary congestion on chest radiogra-
phy or CT scan
• Multiple B-lines on lung ultrasound4
• Elevated pulmonary capillary pressure on
catheterization
• Increased total lung water on pulse contour and ther-
modilution analysis system
• Signs of elevated filling pressures on echocardiography5
• Significant elevation of natriuretic peptides6
(1) Respiratory distress: Acute increase in the work of breathing (assessed
by single inspection), significant tachypnea (RR > 25breaths/min)a, may
be with the use of accessory muscles or abdominal paradox
(2) Crackles ± wheezes over the lungs, third heart soundb
(3) Oxygen saturation on room air by pulse-oximetry (SpO2) <90%.
Arterial blood gases may also show PaO2 < 60 mmHg,
PaCO2 > 45 mmHg or PaO2/FiO2 < 300 mmHg
(4)>_3 B-Lines in two chest zones on each hemithorax7,8
(5) E/E0 > 15. Other parameters of elevated left atrial pressure may
also be considered
(6) Natriuretic peptidesc BNP > 400 or N-ProBNP > 900 (or 1800
in > 75 years)
aRespiratory rate may be lower and orthopnoea may be absent in obtunded
patients.
bPatients with low systolic blood pressure (i.e. <90 mmHg) may be considered to
have cardiogenic shock rather than ACPE.
cIn ‘flash pulmonary oedema’ BNP may be lower.
RR, respiratory rate; CT, computer tomography.
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play an important role in the genesis of this syndrome. Patients with
ACPE often present hypertension on admission. Those who have
hypertensive ACPE more frequently show preserved left ventricular
(LV) ejection fraction (EF), hypercapnia, but they have a lower EI rate
and a better prognosis than those with lower blood pressure.9 Many
of them may have a very rapid presentation, commonly termed ‘flash
ACPE’, without previous clinical signs of accumulation of fluids.10
Cardiogenic shock (CS): When CS is secondary to LV failure, acute
RF is nearly always present, with concomitant pulmonary oedema
and tissue hypoperfusion. In addition to pulmonary oedema, the
reduction in lung perfusion produces an increase in pulmonary dead
space (some ventilated areas receive less blood), increasing the ven-
tilation–perfusion mismatch. In addition, systemic circulatory failure
precipitates metabolic acidosis (lactic acidemia), that increases the
compensatory respiratory load, and reduces central venous oxygen
content (SvO2) by an augmented arterio-venous difference (greater
tissue oxygen extraction). These abnormalities exacerbate the RF
in CS.
Other scenarios: Patients with AHF often have concomitant COPD,
asthma, pneumonia, large pleural effusion, atelectasis or pulmonary
embolism, which may precipitate or aggravate RF. Further, in isolated
right ventricular (RV) failure, RF is mainly seen in cases of acute pul-
monary thrombo-embolism or decompensated chronic pulmonary
hypertension.
Rationale for non-invasive
ventilation in acute heart failure
The net effect of PIP is an increase in oxygenation and a decrease in
the work of breathing.11 In the case of ventilatory support, an addi-
tional improvement in alveolar ventilation should be expected, with
further decreases in the work of breathing and carbon dioxide levels.
However, positive pressure changes heart–lung interactions, with
haemodynamic and respiratory effects (Table 2), including a tendency
to reduce cardiac output and blood pressure. Conversely, in AHF
patients with elevated preload and afterload, it may increase cardiac
output by reducing both pre- and afterload12,13 and reducing intrapul-
monary shunting.14 Finally, when there is isolated RV dysfunction,
positive pressure may be detrimental as the increase in RV afterload
may precipitate or aggravate RV failure.
Modalities of non-invasive
ventilation
Table 3 shows the features of the most commonly used modalities of
NIV in acute settings. The main applications are continuous positive
airway pressure (CPAP), non-invasive pressure support ventilation
(NIPSV), and more recently, high-flow nasal cannula (HFNC).
Continuous positive airway pressure (CPAP) is the simplest NIV techni-
que and consists of the application of continuous positive pressure
into the lungs (Figure 1). It can be applied without the aid of a ventila-
tor, by using a source of air or oxygen to renew the air through a her-
metically sealed mask equipped with positive end expiratory
pressure (PEEP) valve, or with the Boussignac system.15
Non-invasive pressure support ventilation (NIPSV): This modality, the
core of NIV, requires a ventilator. It is programmed with two levels
of pressure: expiratory pressure (EPAP) or PEEP, and inspiratory
pressure (IPAP), which is obtained with pressure support (See Figure
2). It is also called non-invasive intermittent positive pressure ventila-
tion (NIPPV), or sometimes bilevel or BiPAP. The final result is equiv-
alent to a CPAP mode with inspiratory assistance. This method
requires some experience for setting the ventilator to the changing
needs of the patient. Adequate synchrony is essential. The respira-
tory rate is not pre-set and depends exclusively on the patient.
High-flow nasal cannula (HFNC): This system delivers a heated and
humidified oxygen–gas mixture (up to 60–80 L/min) that exceeds
patients’ spontaneous inspiratory demand through a nasal cannula
adjusted to the nostrils (Figure 3). There are beneficial actions: a low
level of PEEP (<5 cmH2O); a washout effect in nasopharyngeal.
16 It
should be noted that with an open mouth, the PEEP effect practically
disappears.17 This could be a disadvantage in ACPE patients with
severe dyspnoea who generally mouth breath.
Other modalities: See Table 3 for explanations.
Evidence and recommendations
for the use of non-invasive
ventilation in acute heart failure
syndromes
Continuous positive airway pressure and
non-invasive pressure support ventilation
in acute cardiogenic pulmonary oedema
Acute cardiogenic pulmonary oedema is the second most frequent
indication for NIV.18 The first randomized trials performed at the end
of the 1980’s using CPAP, showed faster improvement of RF than
COT19,20 with a reduction in EI rate.20 The first randomized trial of
Table 2 Main physiologic effects of positive
intrathoracic pressure
Cardiovascular
# Venous return ! # RV preload ! # LV preload
" Pulmonary vascular resistance ! " RV afterload ! RV enlargement
!# LV Compliance
# LV afterload (# systolic wall stress)
# Systemic blood pressure ! # Cardiac outputa
Respiratory
Recruitment of collapsed alveoli ! "Functional residual capacity
Maintenance continuously opened alveoli! Gas exchange during the
whole respiratory cycle
Intra-alveolar pressure against oedema
# Work of breathing
" Oxygenation
aIn patients with AHF with elevated LV preload and afterload, cardiac output may
increase as consequence of the application of positive intrathoracic pressure.
RV, right ventricle; LV, left ventricle.
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NIPSV in ACPE, published in 2000, showed similar results.21 Several
meta-analyses22–24 revealed both techniques reduced the EI rate, and
tended to reduce mortality as compared to COT, a trend that was
statistically significant for CPAP. However, in 2008, a large random-
ized trial (3-CPO) including 1069 patients with acidotic (pH < 7.35)
ACPE assigned to CPAP, NIPSV, or COT,25 showed no difference in
mortality, although both NIV techniques improved respiratory dis-
tress faster than COT. There may be several explanations for the dis-
crepancy between this trial and the prior meta-analyses. The first is
the population studied: nearly one-third of the trials included in the
....................................................................................................................................................................................................................
....................................................................................................................................................................................................................
....................................................................................................................................................................................................................
....................................................................................................................................................................................................................
....................................................................................................................................................................................................................
....................................................................................................................................................................................................................
....................................................................................................................................................................................................................
Table 3 Main modalities of NIV
Main characteristics Advantages Disadvantages Main indication
CPAP Continuous positive intra-
thoracic pressure
Very simple use Does not provide ventilatory
help on inspiration
ACPE
Does not require a ventilator Atelectasis
Obstructive sleep apnoeaImproves oxygenation
HFNC High humidified flow (up to
60–80 L/m) through nasal
cannula, producing:
• Low level of PEEP
• Decreased upper airway
resistance
• Tracheal air washout
Simple use Does not provide ventilatory
help on inspiration
Sub-acute ACPE
Does not require a ventilator AHF needing prolonged NIV
Hypoxaemic respiratory
failure
Good adaptation
Weaning from mechanical
ventilation
Improves oxygenation
NIPSV Inspiration: Decelerated flow
to maintain a target pres-
sure (pressure support)
triggered by patient’s
effort.
Provides ventilatory support Needs expertise and appro-
priate device.
ACPE
AHF and COPDResults as a continuous posi-
tive pressure plus a help
on inspiration
May produce overassistance
when patients increase
inspiratory effort
Hypercapnic respiratory
failure
Expiration: PEEP
Weaning from mechanical
ventilation
PAV Adjusts ventilator assistance
to the activity of respira-
tory muscles estimated by
an algorithm, proportion-
ally to the patient’s effort
Provides ventilatory support Mismatching in complex res-
piratory pattern
Potentially indicated in
patients with asynchrony
with NIPSV
Better adaptation than
NIPSV
It has been used in ACPEMay prevent overassistance
APC-AVAPS Changes inspiratory pressure
to maintain constant a tar-
get volume
Provides ventilatory support Tidal volume limitation is not
guaranteed in higher inspir-
atory drive
COPD encephalopathy
Ensures minute ventilation Hypoventilation syndrome
High pressures in cases of
low lung compliance
No indication in AHF
NAVA Inspiratory support triggered
by diaphragm contraction
Earliest trigger and maximal
adaptation to patient’s
inspiratory drive
Requires oesophageal
catheter
More commonly used in
intubated patients
No indication in AHF
ASV Changes inspiratory pressure
and PEEP according to the
respiratory pattern of the
patient
Provides ventilatory support May be harmful in patients
with chronic heart failure
sleep disorders and low EF
Complex sleep disorders
Ensures minute ventilation
and adapted PEEP, avoiding
apnoeas
It has been used in ACPE
CPAP, continuous positive airway pressure; NIPSV, non-invasive pressure support ventilation; HFNC, high-flow nasal cannula; PAV, proportional assist ventilation; APC-AVAPS,
adaptive-pressure-control (APC) or average volume-assured pressure support; NAVA, neurally adjusted ventilatory assist; ASV, adaptive servoventilation; ACPE, acute cardio-
genic pulmonary oedema; PEEP, positive end expiratory pressure; AHF, acute heart failure; EF, ejection fraction; COPD, chronic obstructive pulmonary disease.
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meta-analyses were performed in ICUs, suggesting that were sicker
patients, and in fact, showed higher rates of EI (21.9% vs. 2.9%) and
mortality (15.3% vs. 9.6%).26 In addition, the patients in 3-CPO were
not hypoxaemic (mean PaO2 was 100 mmHg in the three arms at
study entry), meaning that a clear advantage from NIV in might not
be easily shown in patients with mild RF and very low EI rate. The sec-
ond argument concerned crossover. There was a high crossover rate
in 3-CPO (nearly 20% of the patients) mainly due to discomfort
(intolerance) in NIV groups, or worsening RF in the COT group
(which was significantly higher than in the NIV groups). Finally,
although the effect of NIV on mortality after the 3-CPO remains
inconclusive, a subsequent meta-analysis including this trial, showed
that both modalities reduced the EI rate and still CPAP reduced mor-
tality [relative risk 0.64 (95% CI, 0.44–0.92)], mainly in high-risk
patients with acute coronary syndromes.27
There are no specific trials focused on patients with hypertensive
ACPE, but in this case, NIV may be used to improve symptoms.28
Several studies have shown that the early application of CPAP in
the pre-hospital care of patients with ACPE improved RF faster than
COT, with a tendency to reduce the EI rate.29–31 Because CPAP
does not require special training or expensive equipment it can be
recommended in this setting.
Recent surveys have shown a dramatic expansion in use of NIV in
the general population in the last decades, particularly in ACPE,32 but
with a wide variation among centres.33 Data from 2430 patients who
required ventilatory support in the ADHERE registry, supported the
use of NIV to avoid EI.34
The latest ESC guidelines have given NIV a Class IIa recommenda-
tion with level of evidence B35,36 in patients with respiratory distress
(respiratory rate > 25 breaths/min, SpO2 < 90%). The NICE guide-
lines in AHF recommended NIV in patients with ACPE with severe
dyspnoea and acidemia.37 Finally, e very recent guidelines from ERC/
ATS recommend NIV, either bilevel NIV or CPAP, for patients with
ARF due to ACPE and suggest it in the pre-hospital setting.38
We recommend that NIV should be used in patients with ACPE,
as defined above, in order to reverse RF faster, avoid EI and, with
lower evidence, potentially reduce mortality in high risk patients.
Continuous positive airway pressure may be the best option in the
pre-hospital setting.
High-flow nasal cannula in acute heart
failure
In adults, HFNC has recently shown to be effective in the weaning of
patients from mechanical ventilation39,40 and in hypoxaemic RF from
different aetiologies.41
In AHF the data are scarce, with only one randomized study pub-
lished this year. This included 128 patients with ACPE, in which
HFNC only showed a greater decrease in respiratory rate after
60 min compared to COT.42 High-flow nasal cannula has been also
used in stable Class III heart failure patients43 and in a short series of
AHF patients needing prolonged ventilation support.44
In some comparative studies HFNC was better tolerated than
NIPSV,45 which anticipates an expansion of the technique. It can be
recommended in patients needing prolonged ventilation support,
during weaning and in hypoxaemic AHF not tolerating CPAP/NIPSV
or failing COT, although further trials are necessary to establish its
optimal indications.46
Nebulizer
A
B
Figure 1 (A) Pressure/time curves in continuous positive airway
pressure (CPAP). A patient breathing on room air and after the
application of CPAP. (B) Continuous positive airway pressure
Boussignac mask. Boussignac mask with a nebulizer inserted in the
circuit. This mask generates positive end expiratory pressure
through a high transversal flow that creates a barrier effect.
Figure 2 Pressure support (PS) curves. Pressure curves of a
patient breathing on room air, after the application of PS of
12 cmH2O and after adding positive end expiratory pressure (PEEP)
of 10 cmH2O. Blue arrows indicate patient’s inspiratory effort that
triggers the ventilator to deliver a decelerating flow to reach the
preset PS. Inspiration is interrupted when the patient finishes the
inspiratory effort or the flow arrives to a percentage of the peak
(usually 25%). Inspiratory positive airway pressure (IPAP) is the sum
of PS and PEEP, whereas PEEP is equivalent to expiratory positive
airway pressure (EPAP). Note that tidal volumes change in every
cycle according to patient’s effort.
Non-invasive ventilation in acute heart failure 5
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Other modalities in acute heart failure
In a small randomized trial including 36 patients, Proportional Assist
Ventilation showed similar results vs. CPAP.47 In a series of patients
with ACPE from Japan, Adapted Servoventilation resulted slightly better
than COT.48 However, this technique showed a potential increase in
mortality when was applied to treat sleep apnoea in patients with
chronic heart failure and reduced EF49 and therefore, it was consid-
ered Class III in the latest ESC-guidelines.35 Other modalities50,51 pre-
sented in Table 3 have not been tested in AHF.
Non-invasive ventilation and myocardial
infarction
Acute myocardial infarction (AMI) is a frequent cause of ACPE.
However, the clinical picture may be confusing as ACPE often is asso-
ciated with a rise in high-sensitivity troponin, and it may be difficult to
know whether ACPE was precipitated by AMI or whether cardio-
myocyte injury was the consequence of ACPE.52 Two old studies sug-
gested that NIPSV could precipitate AMI. The first comparing NIPSV
to CPAP was prematurely stopped after recruiting 27 patients due to
a higher rate of AMI in the NIPSV group,53 but the majority of patients
already had chest pain on admission, suggesting a recruitment bias
rather than an effect of ventilatory therapy. The second study, started
in mobile intensive care units in Israel,54 compared NIPSV to nitrates
and showed higher rates of AMI (55 vs. 10%) and EI (80% vs. 20%) in
the NIV group. However, patients allocated to the NIV received less
intravenous medical therapy and the protocol imposed strict ventila-
tor restrictions, resulting in a very low pressure support (average:
5 cmH2O) that could have led to hypoventilation. This may have con-
tributed to the poor results with NIV in this trial, as low tidal volumes
may increase alveolar oedema due to the negative intrathoracic pres-
sure precipitated by the patient’s inspiratory effort.55 No other trial
has reproduced these results, including randomized trials specifically
designed to assess this issue,56–58 case–control studies59 or meta-
analyses. In addition, in 3-CPO, NIV was safely used in patients with
AMI, who accounted for nearly 50% of the population enrolled, with
no differences in the incidence of AMI between groups.25 However, it
should be emphasized that patients with ST segment elevation
(STEMI) have not usually been included in the trials. On the other
hand, recent data have shown no effect of oxygen therapy in patients
with suspected AMI without hypoxaemia.60
In summary, there is no relationship between use of NIV and risk
of AMI, and NIV may be considered in patients with ACPE complicat-
ing a Type II AMI or a non-STEMI. Further data are necessary to
assess the role of NIV in patients with STEMI.
Non-invasive ventilation in cardiogenic
shock
There are no studies analysing NIV in this clinical situation.
Traditionally, patients with CS have not been candidates for the
Figure 3 Main interfaces used in non-invasive ventilation (NIV). (A–B) Two different models of total-face mask (probably with the best patient-
ventilator adaptation)69; (C) Oronasal mask: the most used interface; (D) Nasal mask: not indicated in patients breathing by the mouth as those with
acute pulmonary oedema. (E) High-flow nasal cannula: (see text); (F) Helmet: mostly used for continuous positive airway pressure mode, it allows
more patient autonomy (speaking and eating), convenient when anticipating prolonged NIV. Other interfaces like nasal pillows, mouthpieces or laryngeal
masks are usually not considered in acute heart failure.
6 J. Masip et al.
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technique. Although RF is always present in these patients, frequently
altered mental status does not ensure correct spontaneous breathing
and preservation of the upper airway, two conditions necessary for
the appropriate use of NIV. Furthermore, PIP tends to decrease
blood pressure, aggravating hypoperfusion. However, in the
‘Cardshock study’,61 NIV was used in nearly 13% of the patients with
early or non-severe CS, after correction of hypotension, avoiding EI
in the majority.62 Therefore, although the use of NIV remains limited
in hypotensive patients, it may be cautiously considered in selected
CS patients without severe haemodynamic instability. The potential
use of HFNC in this context should be assessed.
Non-invasive ventilation in other acute
heart failure scenarios
There are no randomized studies specifically analysing the effect of
NIV in patients with isolated RV failure. As a general rule, mechanical
ventilation should be avoided in these patients.63 However, in cases
with RF of mixed origin (COPD with pulmonary oedema), NIV may
be especially useful because it may benefit both underlying
conditions.64
Continuous positive airway pressure or
non-invasive pressure support ventilation
Although theoretically NIPSV should be superior to CPAP because it
provides an inspiratory help, no trials or meta-analyses have demon-
strated a clear advantage of one technique over the other for impor-
tant outcomes in patients with AHF, but those treated with NIPSV
have shown faster improvement in several physiological variables in
some trials.53,65–67 In case-series of patients with ACPE, NIPSV was
most clearly effective in those with hypercapnia.21,68 Consequently,
either technique can be used as a first line treatment in ACPE, but it
seems reasonable to prefer NIPSV in patients with severe hypercap-
nia, although little evidence supports this recommendation.
Practical aspects
Equipment
Interfaces
The interface is the component that most defines NIV, and it is crucial
for treatment success. In order to avoid leaks, a tight seal between
the patient’s face and the device is essential, but often difficult to
obtain. There are different types of interfaces (see Figure 3).69
Ventilators
There are three types of ventilators: portable (designed specifically
for NIV), transport, and ICU-ventilators. All of them have particular
settings for CPAP and NIPSV.
Portable NIV ventilators are less expensive have higher mobility,
do not need an air flow source and seem to allow better synchrony
than ICU and transport ventilators.70 A wide range of ventilators is
currently on the market, from the simplest (only pressure is modifi-
able) to the latest generation high-tech ventilators (display monitor-
ing, alarm setting, leakage compensation, different triggers, cycling
and flow ramp control, etc.). The most important attribute of the
equipment is leakage compensation through an increase of air flow
(up to 120–180 L/min).
Complements
Skin protectors are recommended. Heat humidification or heat and mois-
ture exchangers are recommended because they may facilitate NIV.71
Nebulizers can be used safely without interrupting NIV therapy.
Sedation: Mild sedation decreases respiratory rate and intoler-
ance72,73 and is used nearly 20% of the patients treated with NIV.74
However, sedation may cause adverse events (hypoventilation, hypo-
tension and also, vomiting or aspiration with opioids) and should be
used only in patients who remain uncooperative or who show poor
synchrony with the ventilator, and then only after non-
pharmacological approaches have been tried75 (e.g. changing the
interface, tuning the ventilator, reassuring the patient, etc.).
Experienced staff and appropriate monitoring (e.g. targeting a seda-
tion scale or respiratory rate) is essential.76 Minimal intermittent
doses of a single drug may be preferable to continuous infusions or
combinations of different agents.74,75 Morphine (boluses of 2–4 mg)
is the most used single drug in this setting,72 although recent data
raised safety concern of its use in AHF.77 Other opioids, propofol,
midazolam, and more recently dexmedetomidine, which is an
a2-adrenergic receptor agonist with less central respiratory depres-
sion, have been used in this context.75,76
Starting non-invasive ventilation
Before starting the technique, the contraindications for NIV should
be considered (Table 4). Empathic communication between nurses/
physicians and the patient is essential, with clear instructions about
what to expect and frequent encouragement thereafter. By fitting the
mask manually at the onset, patients gain confidence with the techni-
que, and it later may be secured fixed with strips in a similar manner.
Device settings
For NIPSV, it is recommendable to start with low levels of PEEP (3–
4 cmH2O) and pressure support of 7–8 cmH2O, increasing it pro-
gressively according to patients’ adaptation and response. Target tidal
volumes are 4–7 mL/kg (often lower in COPD patients). With
Table 4 Contraindications of NIV
Absolute Cardiac or respiratory arrest
Anatomical abnormality (unable to fit the interface)
Inability to keep patent airway (uncontrolled agitation,
comaa or obtunded mental status)
Refractory hypotension
Relative Mild agitation or poor cooperation
Mild hypotension
Upper gastrointestinal haemorrhage or vomiting
Inability to expectorate copious secretions
Recent frail upper gastrointestinal or airway surgery
Multiorgan failure
Isolated right ventricular failure
aModalities like NIV with volume controlled or ‘Average volume assured pressure
support’ have been used in hypercapnic encephalopathy.
Non-invasive ventilation in acute heart failure 7
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.. pressure support of 10–18 cmH2O and PEEP of 4–7 cmH2O (IPAP
15–20 cmH2O/EPAP 4–7 cmH2O), a suitable ventilation is generally
achieved. High pressures may cause excessive air leakage, asynchrony
(especially in patients with high respiratory rate) and discomfort.
With portable ventilators, a PEEP over 4 cmH2O is usually necessary
to avoid rebreathing. FIO2 should be titrated up to 100% to achieve
the desired SpO2.
When using CPAP, it is advisable to start with 5 cmH2O, increasing
soon to 7.5 or 10 cmH2O, according to the response. When using
HFNC in critically ill patients, it is often started with a FIO2 of 100%
and the maximum tolerated flow. Later, FIO2 and flow rate can be
decreased according to SpO2
41 and patient’s demand. In less severe
cases, it is usually started with lower flow and FIO2.
Monitoring non-invasive
ventilation
To ensure the success of NIV, close monitoring is necessary
(Table 5), especially respiratory rate (patient’s effort), oxygen satura-
tion (FIO2 may need to be adjusted), and pH/PaCO2 (to assess effi-
cacy). Visualization of flow and pressure waveforms on a continuous
display is recommended78 (Figure 4). In addition to continuous obser-
vation, general reassessment is recommended at 60 and/or
90–120 min, with special attention paid to risk factors for failure.79
The key issue is optimal synchronization between the patient’s spon-
taneous breathing and the ventilator.80–82 Air leakage is often
involved in cases of asynchrony, which may be reduced by one or
more of adjusting the mask, shortening inspiration time, changing
Table 5 Monitoring NIV
Patient
Respiratory rate
Other vital signs
Dyspnoea/accessory muscle use/abdominal paradoxical breathing
Level of consciousness
Comfort with the interface
Collaboration
Ventilator parameters
Tidal volume (>4 mL/Kg: 6–7 mL/Kg) and minute ventilation
Air leakage volume (<0, 4 L/s or < 25 L/min)
Pressure support and PEEP settings
Asynchrony (ineffective efforts, auto-triggering, double-triggering,
short/long cycle)a
Trigger/slope (ramp)/Inspiration time/expiration settings
Auto-PEEP
Alarms (apnoea or high respiratory rate, low/high minute ventilation,
others)
Gas exchange
Continuous pulse-oximetry (SpO2)
Arterial or venous blood gas samplesb
Risk factors of failure
Before initiation
Lung infection
Altered mental status
Hypotension
High severity scores
Copious secretions
Extremely high respiratory rate
Severe hypoxaemia in spite of high FIO2
After initiation
Inappropriate ventilator settings
Unfitting interface
Excessive air leakage
Asynchrony with the ventilator
Poor tolerance to NIV
After 60–90 min
No reduction in respiratory rate or carbon dioxide
No improvement in pH or oxygenation (#SpO2 or #PaO2/FiO2)
Signs of fatigue
Neurological or underlying disease impairment
Criteria for endotracheal intubation
Cardiac or respiratory arrest
Progressive worsening of altered mental status
Progressive worsening of pH, PaCO2, or PaO2 despite NIV
Progressive signs of fatigue during NIV
Need to protect the airway
Persistent haemodynamic instability
Agitation or intolerance to NIV with progressive respiratory failure
aSee also Figure 4.
Asynchrony: Ineffective efforts: inspiratory efforts not followed by a cycled
response from the ventilator. Auto-triggering or double-triggering: cycled respira-
tions out of patients’ demand. These asynchronies should be managed by reduc-
ing the leakage, tuning the inspiratory trigger, and adjusting the level of pressure
support. Prolonged cycle (delayed cycling off): cycled mechanical inspiratory time
longer than patient’s inspiratory time. It may be compensated by reduction of
leakage, decrease of pressure support, inspiratory time or ramp, and when avail-
able, titration of expiratory trigger. Auto-PEEP: air trapping due to a limitation of
the expiratory airflow. Observed in COPD and cases with high respiratory fre-
quency. Treated with measures to extend expiratory time and decrease respira-
tory rate, titrating PEEP (compensate 80% of the auto-PEEP in COPD patients).
bBaseline and after 60–90 min of NIV for: PaO2/FiO2, pH, PaCO2, and bicarbon-
ate; venous samples are suitable for pH, bicarbonate, and SvO2.
PEEP, positive end-expiratory pressure; PaO2, arterial partial oxygen pressure;
PaCO2, arterial partial carbon dioxide pressure; FiO2, fraction of inspired oxygen;
SpO2, oxygen saturation by pulse-oximetry; NIV, noninvasive ventilation.
A B
Figure 4 Pressure and flow curves in non-invasive pressure sup-
port ventilation (NIPSV). (A) Non-invasive pressure support ventila-
tion delivered with a cycling off of 25% of the maximal peak flow.
(B) Decrease of the inspiratory time after the reduction of the ramp
and the increase of the cycling off to 40%. Example of flow curve
with Auto-PEEP (the expiratory flow does not arrive to 0). PEEP,
positive end expiratory pressure; PS, pressure support.
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..pressure support by steps of 2 cmH2O or moving inspiratory and
expiratory triggers (when available) by steps of 5–10% or finally, giv-
ing sedation. In general, a leak <0.4 L/s may be tolerated (<25 L/min).
When to stop
Non-invasive ventilation is usually stopped when a satisfactory recov-
ery has been achieved (usually 2–5 h in ACPE) or conversely, if there
are signs of NIV failure, requiring EI (Table 5). After mid- or long-term
use of NIV (>24 h), a weaning83 period is often carried out, by
decreasing FIO2, PEEP, and ventilation settings progressively. Early
mobilization may shorten this process. With FIO2 <0.5 and flow
rate < 20 L/m, HFNC can be safely replaced by COT.
Conclusions
In AHF syndromes NIV should be used in patients with ACPE. It may
be considered in other AHF patients with RF associated with lung dis-
ease and in some cases of CS, after stabilizing the blood pressure.
Continuous positive airway pressure is a simpler technique that is
recommended as first line therapy in these scenarios, particularly in
the pre-hospital setting or in less well-equipped areas. Non-invasive
pressure support ventilation is equally effective in ACPE and may be
preferable, by experienced teams, in patients with significant hyper-
capnia. High-flow nasal cannula may be an alternative, especially in
patients with AHF requiring prolonged NIV, but is a well-tolerated
NIV technique with wider potential indications.
The overall approach for the use of NIV in AHF, as a complement
to recent ESC consensus papers and guidelines,35,84–86 is shown in
Take-home Figure.
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